Chemical compounds

US10954211B2 · kind B2 · utility

Assignee

• ASTRAZENECA AB · SE

Inventors

• Susanne Elisabeth Berglund · Timrå, SE
• Stephen Connolly · Loughborough, GB
• Martin Hemmerling · Timrå, SE
• Nafizal Hossain · Lund, SE
• Anna Kristoffersson · Lund, SE
• Johan Rune Michael Lundkvist · Macclesfield, GB
• Grigorios Nikitidis · Lund, SE
• Lena Elisabeth Ripa · Lund, SE
• Igor Shamovsky · Mölndal, SE

Key dates

• Filing date: May 10, 2019
• Grant date: Mar 23, 2021
• Expiry date: May 10, 2039

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P11/06
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of a formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an ENaC mediated disease state (such as asthma, CF or COPD).